Oligometastatic PCa & Treatment with ... - Advanced Prostate...

Advanced Prostate Cancer

20,782 members25,887 posts

Oligometastatic PCa & Treatment with Curative Intent

pjoshea13 profile image
4 Replies

New study below.

The paper's title isn't very helpful:

"PD24-11 EVALUATION OF A MULTIMODAL STRATEGY TO ACCELERATE DRUG EVALUATIONS IN EARLY STAGE METASTATIC PROSTATE CANCER"

Here is the conclusion:

"Treatment directed at all sites can eliminate detectable disease in selected patients with newly diagnosed metastatic prostate cancer. A multimodal treatment strategy inclusive of the NED endpoint for patients who present with disease that is beyond the limits of curability by any single modality should be considered to enable the evaluation of new approaches in order to prioritize large-scale testing in early stages of advanced disease."

Oligometastatic disease involves no more than a handful of metastases. The old idea was that if there was one metastasis, there would inevitably be others. But in some men, that is not the case. Which opens up the possibility of aggressive treatment.

Here's how ScienceDaily covered the study:

sciencedaily.com/releases/2...

-Patrick

jurology.com/article/S0022-...

The paradigm of first testing systemic treatments in advanced disease followed by development in earlier disease states and finally large-scale trials evaluating whether the approach, in combination with local therapy, can prevent or delay the time-to-event measures of disease progression or death in patients with ″high-risk″ tumors is no longer practical now that 6 life-prolonging systemic therapies in metastatic castration-resistant prostate cancer are available. Our objective was to evaluate a multimodal treatment platform and a short term endpoint of treatment efficacy as a new strategy to rapidly evaluate and prioritize regimens for large-scale phase 3 testing.

We conducted a pilot study of twenty men with oligometastatic M1a (extrapelvic nodal disease) or M1b (bone disease) at diagnosis. All sites of disease were treated using a multimodal approach that included androgen deprivation (ADT), radical prostatectomy plus pelvic lymphadenectomy (retroperitoneal lymphadenectomy in the presence of clinically positive retroperitoneal nodes), and stereotactic body radiotherapy to osseous disease and/or the primary site. ADT was discontinued in responding patients. Outcomes of each treatment were assessed sequentially. The primary endpoint of ″no evidence of disease″ (NED) was defined by an undetectable PSA (<0.05 ng/mL) with noncastrate levels of testosterone at 20 months (>150 ng/dL).

Each treatment modality contributed to the outcome: 95% of the cohort achieved an undetectable PSA with multimodal treatment, including 25% of patients after ADT alone and an additional 50% and 20% after surgery and radiotherapy, respectively. Overall, 20% of patients (95% confidence interval 3-38%) achieved the primary endpoint, which persisted for 5, 6, 27+, and 46+ months. All patients meeting the primary endpoint had been classified with M1b disease at presentation.

Treatment directed at all sites can eliminate detectable disease in selected patients with newly diagnosed metastatic prostate cancer. A multimodal treatment strategy inclusive of the NED endpoint for patients who present with disease that is beyond the limits of curability by any single modality should be considered to enable the evaluation of new approaches in order to prioritize large-scale testing in early stages of advanced disease.

Written by
pjoshea13 profile image
pjoshea13
To view profiles and participate in discussions please or .
Read more about...
4 Replies
eggraj8 profile image
eggraj8

Fascinating article on metastatic prostate cancer treatment

Dan59 profile image
Dan59

As always thank You for your research Patrick, You really keep us sand all the men to follow us on this site up to date on the latest research , and we are grateful.

Dan

BigRich profile image
BigRich

Patrick,

You have given me food for thought.

Thank you,

Rich

Sisira profile image
Sisira

Definitely a "silver-line in a dark cloud" ! A MULTIMODAL STRATEGY can obviously be a trusted approach like a "Multi barrel/multi prong strong missile attack" in a war. Although I learned a lot about treatment for Oligometastatic PCa disease from talks given by Dr.Kwon of Myo Clinic, I did't know about this Multimodal approach clearly. How to motivate our oncologists to look at these new approaches will be more difficult than finding a "cure" for the cancer!

Thanks for your useful post.

You may also like...

Oligometastatic PCa - My New Treatment Plan

PET scan showed no active cancer outside the prostate and no sign of cancer in circulating tumor...

Radiation & Oligometastatic PCa.

with low-volume disease....

MDT and Intermittent ADT for Oligometastatic PCa

-intermittent-hormone-therapy-for-oligometastatic-prostate-cancer-extend-a-multicenter-randomized-ph

TIMING questions for a multimodal approach oligometastatic PCa with CVD

cardiologist. The idea is a multimodal aggressive approach for oligometastatic PCa (T3b N1 M1,...

Any Curative Treatments after RT as Sole Primary Treatment?

about RT as a treatment after RP with BCR, but don't see much when RT has been sole treatment. (See...